T-DXd is recommended as second-line therapy in patients with metastatic HER2-positive breast cancer who have progressed during or after treatment with trastuzumab, pertuzumab, and chemotherapy (expert recommendation). The gene discussed is ERBB2; the disease is breast carcinoma.